semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Patients with active acromegaly (based on elevated GH and IGF-1 levels) Patients who have undergone one or more pituitary surgeries, but have not been treated medically, or de-novo patients presenting a visible pituitary adenoma on MRI and who refuse pituitary surgery or for whom pituitary surgery is contraindicated Patients for whom written informed consent to participate in the study has been obtained prior to any study related activity  Patients who are being or were treated with octreotide, lanreotide, dopamine agonists or GH antagonists with the exception of a single dose of short-acting octrotide or short-acting dopamine agonists. In case of a single dose of short-acting octrotide, the dose should not be used to predict the response to the octretide treatment. The single dose of short-acting octreotide or short-acting dopamine agonists should not be administered in the 3 days prior to randomization Patients with compression of the optic chiasm causing any visual field defect Patients who have received pituitary irradiation within the last ten years prior to visit 1 Poorly controlled diabetic patients Other protocol-defined inclusion/
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Brain and Central Nervous System Tumors Clinically demonstrable invasive pituitary macroadenoma, including any of the following subtypes Growth hormone-secreting Prolactin-secreting Adrenocorticotrophic hormone-secreting Non-secreting Must have biochemical evidence of any of the following Acromegaly as measured by serum insulin-like growth factor-1 (IGF-1) Prolactinoma as measured by serum prolactin (PRL) Cushing's disease as measured by 24-hour urinary-free cortisol Inadequate tumor control, defined as a visible pituitary tumor ≥ 1 cm in maximal diameter encasing the carotid arteries, and/or invading into the cavernous sinuses, and/or abutting/invading the optic chiasma as demonstrated by MRI scan with or without contrast
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Cushing's Disease Clinically demonstrable ACTH-secreting pituitary tumor Pituitary tumor demonstrated on MRI with and without contrast AND/OR evidence of a central ACTH source following inferior petrosal sinus sampling Newly diagnosed disease Biochemically active disease that is not adequately controlled, as demonstrated by the following standard Elevated 24-hour urinary-free cortisol levels on at least 2 separate 24-hour urine collections 1 week apart Lack of suppression of serum cortisol to < 1.8 μg/dL (at 8 am) following administration of 1 mg of dexamethasone at 11 pm the night before Measurable plasma ACTH levels Patient is hypercortisolemic and does not wish to receive alternate steroid-lowering therapy, such as ketoconazole and/or metyrapone Patients with evidence of optic nerve or chiasm compression on post-operative MRI must have a normal visual field evaluation by Goldman perimetry No visual field abnormalities
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Acromegaly Patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach or with first-line depot SSA treatment Achieving control of the disease; AND With available follow-up after 12 months of treatment  Patients receiving second surgery within 3 months from first surgery Requiring combined dopamine-agonists and SSA because of a mixed GH/PRL-secreting tumor Receiving the s.c. octreotide for longer than 15 days; OR Requiring surgery or SSA as second-line treatment before the completion of the 12 months or with a follow-up shorter than 6 months after surgery or pharmacotherapy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Acromegaly No previous treatment for acromegaly  primary surgery concomitant hyperprolactinemia requiring combined somatostatin analogues and dopamine-agonist treatment primary treatment with lanreotide
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Brain and Central Nervous System Tumors Clinically demonstrable pituitary tumor, including either of the following subtypes ACTH-secreting adenoma Residual or recurrent disease ≥ 1 month after prior pituitary surgery Clinically demonstrable tumor, as evidenced by both of the following Elevated 24-hour urinary free cortisol (UFC) level Lack of suppression of 8 a.m. serum cortisol to < 1.8 µg/dL after administration of dexamethasone 1 mg at 11 p.m. the previous night Tumor demonstrated by MRI performed with and without contrast and/or by inferior petrosal sinus sampling with evidence of a central ACTH source Normal visual field evaluation by Goldman perimetry Hypopituitarism allowed as evidenced by any or all of the following Subnormal growth hormone (GH) response to arginine/GH-releasing hormone testing (normal response is an increase of 2-6 ng/me)  Acromegaly as demonstrated by normal serum insulin-like growth factor-1 (IGF-1) level Cushing disease as demonstrated by normal 24-hour UFC cortisol level Prolactinoma as demonstrated by normal to moderately elevated prolactin levels (moderate elevations in serum prolactin [< 200 ng/mL] can occur in non-secreting tumors due to pituitary stalk displacement) clinically significant renal, hematologic, cardiac, or hepatic abnormalities within the past month other active malignancy within the past five years except basal cell carcinoma or carcinoma in situ of the cervix evidence of drug or alcohol abuse prior or current medical condition that may interfere with the conduct of the study or evaluation of its results, in the opinion of the Investigator or the Data Safety Monitoring Board compliance officer postmenopausal female receiving HRT pregnant or nursing history of immunocompromise, including known HIV positivity as measured by enzyme-linked immunosorbent assay and western blot
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly To be eligible for entry in this study, patient must Be greater than or equal to 18 years of age Have a confirmed diagnosis of acromegaly based on the following 1. Typical clinical features and 2. Mean GH concentration > 1.0 ng/mL following an oral glucose tolerance test (OGTT) and 3. Elevated serum IGF-1 levels above gender and age matched values Fall into one of the following categories: 1. Has been treated for at least the last 12 weeks with Sandostatin LAR® 10 mg or 20 mg, every 28 days with well-controlled symptoms of acromegaly and GH concentration < 2.5 ng/mL at screening or 2. Be naïve to prolonged release octreotide with a demonstrated tolerance response to a 7-day administration of Sandostatin® immediate release (50 µg s.c. t.i.d.) or 3. If previously treated with prolonged release octreotide, has stopped such treatment for at least 12 weeks prior to screening If female and of childbearing potential, must have a negative pregnancy test at screening and be using adequate means of birth control (i.e., oral or trans-dermal contraceptive drugs, intra-uterine device, diaphragm) during the study Have the ability to understand the requirements of the study, provide written informed consent to participate in this study and agree to abide by the study restrictions  To be eligible for entry in this study, patient must NOT If female, be pregnant or lactating Have been treated with a GH receptor antagonist (pegvisomant) within the last 12 weeks Have used a dopamine agonist within the last 30 days Have undergone pituitary surgery within the last 12 weeks Have undergone radiotherapy within the last two years Have any contraindication (hypersensitivity to octreotide formulation) or non-responders to Sandostatin-LAR® treatment Be currently treated with Sandostatin-LAR® and have symptoms of acromegaly that would justify, in the Investigator's opinion, a dose modification Be receiving Sandostatin-LAR® administration every < 21 or > 35 days Have a liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or has persistent ALT, AST > 2 X ULN, serum creatinine > 2 X ULN, serum bilirubin > 2 X ULN
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Quality of Life Acromegaly Active acromegaly Serum total IGF-I levels must have been normalized during long-term treatment with long-acting somatostatin analogs Age between 18 and 80  Any contra-indication for the use of long-acting somatostatin analogs, as e.g. the use of anti-coagulants Subjects with pituitary tumors that compress the optic chiasm Patients with insulin dependent diabetes Patients with cancer Patients with kidney or liver function disturbances Fertile female patients that refuse to take contraceptives during the study
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Growth Hormone Deficiency Pituitary Tumor Adult patients with a history of a nonsecreting pituitary tumor with or without prior pituitary surgery  Current use of GH therapy or within the prior 3 months. Pituitary tumor necessitating surgery
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Insulin Resistance Impaired Glucose Tolerance Age > 18 Diagnosed with acromegaly Safe anticonceptive for fertile women Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH < 0.5 µg/l.)  Pregnancy Liver disease Diabetes mellitus type I Magnetic or electronic implants
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cushing's Syndrome Insulin Resistance Written consent Age between 18 and 70 Diagnosed with Cushing's syndrome  Suspected malignancy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Growth Hormone Deficiency Adult male age 25-65 with documented growth hormone deficiency on stable doses x 3 months (at least) of any hormone replacement therapies and with stable MRIs x 2 years in the setting of a known pituitary mass  Female gender current GH use or GH use within three months of the study diabetes hypoglycemia liver or kidney disease use of drugs that could increase GH secretion (i.e. L-dopa) alcohol or substance abuse use of investigational drugs within four weeks of our study and use of supraphysiologic doses of steroids within the previous six months
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Acromegaly The patient must have a clinical diagnosis of acromegaly The patient must be treated with Somatuline® Depot (including patients newly prescribed Somatuline® Depot) The patient or legally authorized representative must be able to understand the protocol and give signed informed consent. Assent from the patient should also be obtained, where appropriate. Signed informed consent and assent must be obtained before any study-related activities are conducted  Symptomatic, untreated biliary lithiasis Known hypersensitivity to somatostatin analogs or related compounds (e.g., octreotide)
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly Patients treated with either first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach or with first-line depot SSA treatment, or both and Patients with available follow-up after 60 months of treatment  Patients requiring dopamine-agonists or pegvisomant Patients receiving the s.c. octreotide for longer than 15 days Patients receiving radiotherapy Patients with a follow-up shorter than 60 months
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Cancer Cholangiocarcinoma Liver The surgical protocol will initially be offered to liver transplant candidates with de novo hilar CCA or CCA arising in the setting of PSC. Diagnosis of CCA will be established by intraluminal brush cytology, intraluminal biopsy, or a carcinoma antigen (CA) 19.9 level greater than 100 ng / mL in the setting of a radiographic malignant stricture. Biliary aneuploidy demonstrated with DIA and FISH will be considered equivalent to cytology. All patients with CCA will be evaluated by the liver transplant team which includes experienced hepatobiliary and liver transplant surgeons. Patients will be presented at the weekly liver transplant selection conference to assess their candidacy as well as the weekly GI Multidisciplinary Tumor Conference at the Huntsman Cancer Institute. Clinical staging prior to neoadjuvant therapy will chest and abdominal computed tomography, liver ultrasound, and bone scan. Patients will also undergo endoscopic ultrasound with fine needle aspiration of suspicious lymph nodes. All patients will undergo staging laparoscopy to rule out the presence of peritoneal disease followed by staging laparotomy. Patients with N1 disease (metastasis to lymph nodes within hepatoduodenal ligament) will remain eligible for the protocol. Tumor size will not be included in the   Patients with evidence of disease progression beyond study will not be eligible to continue on to liver transplantation. ** Patients with metastatic disease are not eligible for this trial ** will previous chemotherapy or radiotherapy uncontrolled infection a previous malignance other than non-melanoma skin cancer or in situ cervical cancer within the last five years medical conditions precluding transplantation metastatic disease (including N2 disease), and patients with hilar tumors extending below the cystic duct. Patients with extrahepatic metastases, local spread of disease to adjacent organs, and N2 nodal disease (metastasis to peripancreatic, periduodenal, periportal, celiac, superior mesenteric, and / or posterior pancreaticoduodenal nodes) will be excluded as will patients with extension of tumor into the main portal vein
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 3.0-80.0,  Adrenal Tumors Clinical diagnosis of Benign Adrenal Tumors  Suspected adrenal malignancy clinically Bilateral adrenal disease Pregnant female
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Growth Hormone Deficiency Adults 19 years or older who have undergone transsphenoidal surgery for a clinically non-secreting pituitary adenoma  Currently taking growth hormone, radiation therapy in the past 5 years, changes in dose of other pituitary hormone replacement therapy in past 3 months, taking hydrocortisone (or its equivalent) at a dose of > 30 mg/day, pregnant or nursing women